Seeking Alpha on MSN7d
Pfizer gets FDA accelerated approval for Braftovi
Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a ...
pharmaphorum3d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Hosted on MSN1d
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
PMLiVE4d
Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer
Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) ...
FDA Grants Accelerated Approval To Pfizer's BRAFTOVI Combination For Metastatic Colorectal Cancer
Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved BRAFTOVI (encorafenib) in combination with cetuximab ...
The Pharma Letter4d
FDA approves new use for Pfizer’s Braftovi combo
US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...
Cure Today7d
FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic Colorectal Cancer Subset
Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
Pfizer announces FDA approval of Braftovi combination
Pfizer (PFE) announced that the Food and Drug Administration has approved Braftovi in combination with cetuximab and mFOLFOX6 for the ...
Daily6d
USFDA nod to Pfizer Braftovi Combination Regimen for BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination ...
Morningstar7d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal ...